NCT01471964View on ClinicalTrials.gov

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 20, 2011

Primary Completion Date

February 7, 2017

Study Completion Date

April 10, 2018

Conditions
Non-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Recurrent
Interventions
DRUG

MLN8237 and Erlotinib

Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Fox Chase Cancer Center

OTHER